Insight Molecular Diagnostics Inc
IMDX
NASDAQ
Biotechnology
$4.32
USD
+0.61 (+16.44%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $131.55M
Volume 331.6K
Revenue
$1.67M
TTM
— YoY
Gross Margin
48%
TTM
— YoY
Net Income
$-49.36M
TTM
— YoY
Operating Cash Flow
$-26.95M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.5 | 0.3 | 1.1 | 0.0 | 0.2 |
YoY Growth | — | — | — | — | -53.9% |
Cost of Revenue | 0.2 | 0.1 | 0.6 | 0.0 | 0.1 |
Gross Profit | 0.3 | 0.1 | 0.5 | 0.0 | 0.2 |
Selling, General & Administrative | 4.1 | 3.9 | 4.6 | 5.4 | 4.8 |
Other Operating Expenses | 2.8 | 3.4 | 13.5 | 0.0 | 2.3 |
Total Operating Expenses | 10.2 | 11.2 | 23.9 | 10.3 | 11.6 |
Operating Income | -9.8 | -11.0 | -23.4 | -10.3 | -11.4 |
EBITDA | -9.3 | -10.5 | -8.3 | -9.7 | -10.7 |
Other Income / Expense | 0.1 | 0.2 | 0.5 | 6.1 | 0.2 |
Total Other Income / Expense | 0.1 | 0.2 | 0.5 | 6.0 | 0.1 |
Income Before Income Taxes | -9.7 | -10.9 | -23.0 | -4.3 | -11.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -9.7 | -10.9 | -23.0 | -4.3 | -11.3 |
Consolidated Net Income / Loss | -9.7 | -10.9 | -23.0 | -4.3 | -11.3 |
Net Income Attributable to Common Shareholders | -9.7 | -10.9 | -23.0 | -4.3 | -11.3 |
Basic EPS | -$0.30 | -$0.34 | -$0.71 | -$0.12 | -$0.31 |
Diluted EPS | -$0.30 | -$0.34 | -$0.71 | -$0.12 | -$0.31 |
Basic Shares Outstanding | 32.0M | 32.0M | 32.2M | 34.5M | 36.8M |
Diluted Shares Outstanding | 32.0M | 32.0M | 32.2M | 34.5M | 36.8M |